Braskem Pfd ADR Stock
Heavy losses for Braskem Pfd ADR today as the stock fell by -€0.350 (-17.500%).
With 3 Buy predictions and 2 Sell predictions the community is currently undecided on Braskem Pfd ADR.
Based on the current price of 1.65 € the target price of 4 € shows a potential of 142.42% for Braskem Pfd ADR which would more than double the current price.
Pros and Cons of Braskem Pfd ADR in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Braskem Pfd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Braskem Pfd ADR | -17.500% | -14.948% | -22.897% | -33.468% | -31.818% | -80.357% | -90.407% |
| Braskem Pfd A | -1.910% | -25.243% | -33.621% | -36.885% | -31.250% | -81.311% | -90.723% |
| Ingevity Corp | 0.000% | -0.752% | -0.752% | 40.068% | 32.106% | 42.857% | - |
| PTT Global Chemical -fgn- | -2.540% | 4.348% | 6.077% | 68.421% | 79.439% | 2.674% | -36.424% |
Comments
Braskem (BAK) was upgraded by JPMorgan Chase & Co. from "neutral" to "overweight". They now have a $5.50 price target on the stock.
Show more
Ratings data for BAK provided by MarketBeat
Braskem (BAK) was downgraded by Bank of America Corporation from "neutral" to "underperform". They now have a $2.80 price target on the stock.
Show more
Ratings data for BAK provided by MarketBeat
Braskem (NYSE:BAK) was downgraded by analysts at Citigroup Inc. from a "neutral" rating to a "sell" rating.
Show more
Ratings data for BAK provided by MarketBeat
News
Braskem Q2 Earnings Call Highlights
Key Points
- Interested in Braskem S.A.? Here are five stocks we like better.
- Recurring EBITDA reached $1.043 billion in Q2 2026, with a 24% margin, helped by wider petrochemical spreads and
Braskem Q1 Earnings Call Highlights
Braskem (NYSE:BAK) reported a sharp sequential improvement in first-quarter 2026 recurring EBITDA, while management said cash preservation and